Check out this great #cancerresearch, #generegulation and functional #epigenomics #postdoc #jobopportunity in the lab of new Robert Bosch Center for Tumor Diseases group leader Dr Haiyang Yun Haiyang_Yun #Stuttgart @BoschStiftung jobs.smartrecruiters.com/RobertBoschKra…

Check out the new press release about the great work from Robert Bosch Center for Tumor Diseases group leader Zeynab Najafova about #molecularsubtype-specific #enhancer activity and detection in #pancreaticcancer published in Molecular Cancer Research @BoschStiftung Clinical Research Unit 5002 at UMG idw-online.de/-DJ4IAA

Neoadjuvant FOLFIRINOX 🤜🤛upfront surgery for resectable pancreatic cancer NORPACT-1 out 🔥 now The Lancet Gastroenterology & Hepatology 📈 Median OS 25 vs. 38 months and resection rate did not differ 💉 60% neoadjuvant group had severe adverse event 🚨 🫵Comments?🧐 👉 sciencedirect.com/science/articl…

And the Steven Johnsen Lab RBCT group at Robert Bosch Center for Tumor Diseases also finally has a page! 😊🎉 rbct.de/en/node/57

Congratulations Robyn Kosinsky, William Faubion, and co-authors!! Mayo Clinic Gastroenterology & Hepatology @BoschStiftung Robert Bosch Center for Tumor Diseases

“Don’t listen to anyone who puts you down. Keep going and aspire for the sky. If someone tells you that you can’t, do it, prove them wrong. Listen to yourself and your heart” – Dr Sankari Nagarajan

“My proudest moment was when I finished my PhD. I’m a first-generation academic and my whole family was so proud of what I achieved.” - Dr Sankari Nagarajan Sankari’s studying how some triple negative breast cancers spread. breastcancernow.org/breast-cancer-…

🤩 Thank you Dr. Sankari Nagarajan!! I remain so very proud of you and all you have achieved! Also very excited about all the amazing discoveries you will continue to make!

What an honor to welcome our Baden-Würtemberg Minister of Science Petra Olschowski to the Robert Bosch Center for Tumor Diseases and the #BoschHealthCampus ! 📸: Björn Hänssler, BHC @BoschStiftung

Really proud to achieve this level in my academic career to host both my amazing mentors in Manchester. Steven Johnsen Lab RBCT Carroll Lab Thanks Manchester Breast Centre UoM Biology, Medicine and Health Division of Molecular and Cellular Function UoM for all the organisation and funding. Keep aiming for the sky, Sankari. 💪🏼

🙏On behalf of our Speaker and host of today's #Seminar Series Lars Zender, thank you Steven Johnsen Lab RBCT for visiting and providing us with great insights into your #research!

Enjoyed listening to my friend, colleague and long-time collaborator Prof. Dr. Volker Ellenrieder talk about the present and future perspectives on #pancreaticcancer #treatment (in German). podcasts.apple.com/de/podcast/gas… Clinical Research Unit 5002 at UMG Universitätsmedizin Göttingen (UMG) #Pankreaskarzinom #Bauchspeicheldrüsenkrebs

We’re looking to hire a talented & motivated BTA to join our team and help us tackle the intricacies of intratumoral heterogeneity. The applicant will be(come) proficient in histological analyses including multiplex immunofluorescence staining & scRNA-seq smrtr.io/kFXnq

Congratulations to the Wolf Lab for Tumor Biochemistry on the publication of their new & interesting results related to #RUVBL1/2 function in controlling #MYC activity in #pancreaticcancer in Gut Journal Great work! doi.org/10.1136/gutjnl…

This week several members of the Robert Bosch Center for Tumor Diseases including the entire Steven Johnsen Lab RBCT Lab are attending the 4th German #PancreaticCancer meeting hosted by Clinical Research Unit 5002 at UMG at the Universitätsmedizin Göttingen (UMG) in Göttingen.

So happy & proud to hear Dr. Sankari Nagarajan from The University of Manchester speak at the 4th German #PancreaticCancer Research Meeting hosted by Clinical Research Unit 5002 at UMG in Göttingen! #ProudPapaMoment #JohnsenGroupAlumni

What a great meeting and sooo proud of Tom for winning the poster prize and Joana Aggrey-Fynn for being selected for an oral presentation!

Proud to share our #publication in #CancerResearch AACR: "Metabolic Reprogramming Is an Initial Step in Pancreatic Carcinogenesis That Can Be Targeted to Inhibit Acinar-to-Ductal Metaplasia" Authors & abstract: aacrjournals.org/cancerres/arti… #Science #Munich TU München